Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298896 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
A Phase 2 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00298896 is a Phase 2 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT00298896, a Phase 2 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
Interventions
- DRUG SNS-595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298896
The ClinicalTrials.gov registry entry for NCT00298896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNS-595 is the first listed.
NCT00298896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00298896 about?
NCT00298896 is a clinical study titled "Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer". The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
What is the current status of trial NCT00298896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-02. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00298896?
The interventions under investigation include: SNS-595 (DRUG).
Who is sponsoring clinical trial NCT00298896?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.